Insilico Medicine (HKEX: 3696) has struck a neuroimmune drug discovery collaboration with South Korea-based SK Biopharmaceuticals (KRX: 326030.KS) worth up to USD 2.5 billion, the firm's second deal exceeding USD 2 billion in under three months. The agreement will see Insilico apply its Pharma.AI generative AI platform to discovering, designing, and optimizing novel candidates across neuroinflammatory, neurodegenerative, and rare neurological indications, with SK taking responsibility for all late-stage development and commercialization.
Under the terms announced at the BIO 2026 International Convention, Insilico is eligible to receive up to USD 18 million in combined upfront and near-term milestone payments. The total potential value of USD 2.5 billion encompasses development, regulatory, and commercial milestones, plus single-digit royalties on net sales. Insilico's March 2026 collaboration with Eli Lilly, which covered an existing portfolio of preclinical oral therapeutics across multiple therapeutic areas, carried a USD 115 million upfront against a USD 2.75 billion total.
Deal context
Pharma.AI is an end-to-end generative AI platform spanning three integrated modules — PandaOmics for target identification, Chemistry42 for de novo molecular design and optimization, and Medicine42 for clinical outcome prediction. In the context of this agreement, the platform will be deployed to generate novel candidates across multiple neuroimmune programs from scratch, functioning as a recurring discovery engine rather than delivering a fixed set of assets. Under the deal terms, Insilico nominates optimized preclinical candidates; SK assumes all downstream responsibility from IND-enabling studies through commercialization, leveraging the CNS commercial infrastructure it built around cenobamate (Xcopri), its epilepsy drug and the first novel CNS medicine independently developed and commercialized in the US by a Korean pharmaceutical company.
Neuroinflammation has emerged as a major area of CNS drug development as evidence increasingly links immune dysfunction to neurodegenerative and neuropsychiatric diseases. Insilico's CNS credentials have been accumulating. In January 2026, it received US FDA IND clearance for ISM8969, a brain-penetrant NLRP3 inflammasome inhibitor for Parkinson's disease generated by Chemistry42, and five months later completed first-in-human dosing in that program in collaboration with Hygtia Therapeutics. The company has also expanded an AI-driven CNS collaboration with Tenacia Biotechnology worth up to USD 94.75 million and signed multiple CNS and autoimmune programs with China Medical System in February 2026. The SK deal adds a partner with validated US CNS commercial capabilities to this growing neuroimmune portfolio.